Advertisement

Molecular Medicine

, Volume 19, Issue 1, pp 88–98 | Cite as

Signaling of High Mobility Group Box 1 (HMGB1) through Toll-like Receptor 4 in Macrophages Requires CD14

  • Sodam Kim
  • Sun Young Kim
  • John P. Pribis
  • Michael Lotze
  • Kevin P. Mollen
  • Richard Shapiro
  • Patricia Loughran
  • Melanie J. Scott
  • Timothy R. Billiar
Research Article

Abstract

High mobility group box 1 (HMGB1) is a DNA-binding protein that possesses cytokinelike, proinflammatory properties when released extracellularly in the C23–C45 disulfide form. HMGB1 also plays a key role as a mediator of acute and chronic inflammation in models of sterile injury. Although HMGB1 interacts with multiple pattern recognition receptors (PRRs), many of its effects in injury models occur through an interaction with toll-like receptor 4 (TLR4). HMGB1 interacts directly with the TLR4/myeloid differentiation protein 2 (MD2) complex, although the nature of this interaction remains unclear. We demonstrate that optimal HMGB1-dependent TLR4 activation in vitro requires the coreceptor CD14. TLR4 and MD2 are recruited into CD14-containing lipid rafts of RAW264.7 macrophages after stimulation with HMGB1, and TLR4 interacts closely with the lipid raft protein GM1. Furthermore, we show that HMGB1 stimulates tumor necrosis factor (TNF)-α release in WT but not in TLR4−/−, CD14−/−, TIR domain-containing adapter-inducing interferon-β (TRIF)−/− or myeloid differentiation primary response protein 88 (MyD88)−/− macrophages. HMGB1 induces the release of monocyte chemotactic protein 1 (MCP-1), interferon gamma-induced protein 10 (IP-10) and macrophage inflammatory protein 1α (MIP-1α) in a TLR4- and CD14-dependent manner. Thus, efficient recognition of HMGB1 by the TLR4/MD2 complex requires CD14.

Notes

Acknowledgments

This work was supported by grants from the National Institutes of Health (RO1GM050441). We thank William Buchser in the UPCI Cytometry Core for help with imaging cytometry studies.

Supplementary material

10020_2013_1901088_MOESM1_ESM.pdf (2.3 mb)
Supplementary material, approximately 2.27 MB.

References

  1. 1.
    Ve T, Gay NJ, Mansell A, Kobe B, Kellie S. (2012) Adaptors in toll-like receptor signaling and their potential as therapeutic targets. Curr. Drug Targets. 3:1360–74.CrossRefGoogle Scholar
  2. 2.
    Piccinini AM, Midwood KS. (2010) DAMPening inflammation by modulating TLR signalling. Mediators Inflamm. 2010:672395.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Bianchi ME. (2007) DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 81:1–5.CrossRefGoogle Scholar
  4. 4.
    Evankovich J, Billiar T, Tsung A. (2010) Toll-like receptors in hepatic ischemia/reperfusion and transplantation. Gastroenterol. Res. Pract. 2010:537263.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Langefeld T, Mohamed W, Ghai R, Chakraborty T. (2009) Toll-like receptors and NOD-like receptors: domain architecture and cellular signalling. Adv. Exp. Med. Biol. 653:48–57.CrossRefPubMedGoogle Scholar
  6. 6.
    Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ. (2002) HMGB1 as a DNA-binding cytokine. J. Leukoc. Biol. 72:1084–91.PubMedGoogle Scholar
  7. 7.
    Wang H, et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science. 285:248–51.CrossRefGoogle Scholar
  8. 8.
    Tsung A, et al. (2005) The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med. 201:1135–43.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Yang R, et al. (2006) Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol. Med. 12:105–14.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Zhou RR, et al. (2012) High mobility group box chromosomal protein 1 in acute-on-chronic liver failure patients and mice with ConA-induced acute liver injury. Exp. Mol. Pathol. 93:213–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Sha Y, Zmijewski J, Xu Z, Abraham E. (2008) HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J. Immunol. 180:2531–2537.CrossRefPubMedGoogle Scholar
  12. 12.
    Park JS et al. (2006) High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. Cell Physiol. 290:C917–24.CrossRefGoogle Scholar
  13. 13.
    Yang H, et al. (2010) A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc. Natl. Acad. Sci. U. S. A. 107:11942–7.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Yang H, et al. (2012) Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol. Med. 18:250–9.CrossRefGoogle Scholar
  15. 15.
    Venereau E, et al. (2012) Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 209:1519–28.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Fitzgerald KA, Rowe DC, Golenbock DT. (2004) Endotoxin recognition and signal transduction by the TLR4/MD2-complex. Microbes Infect. 6:1361–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Miyake K. (2004) Innate recognition of lipopolysaccharide by Toll-like receptor 4-MD-2. Trends Microbiol. 12:186–92.CrossRefPubMedGoogle Scholar
  18. 18.
    Triantafilou M, Miyake K, Golenbock DT, Triantafilou K. (2002) Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J. Cell Sci. 115:2603–11.PubMedGoogle Scholar
  19. 19.
    Jacobson K, Mouritsen OG, Anderson RG. (2007) Lipid rafts: at a crossroad between cell biology and physics. Nat. Cell Biol. 9:7–14.CrossRefPubMedGoogle Scholar
  20. 20.
    Pike LJ. (2004) Lipid rafts: heterogeneity on the high seas. Biochem. J. 378:281–92.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Muta T, Takeshige K. (2001) Essential roles of CD14 and lipopolysaccharide-binding protein for activation of toll-like receptor (TLR)2 as well as TLR4 reconstitution of TLR2- and TLR4-activation by distinguishable ligands in LPS preparations. Eur. J. Biochem. 268:4580–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Ohnishi T, Muroi M, Tanamoto K. (2007) The lipopolysaccharide-recognition mechanism in cells expressing TLR4 and CD14 but lacking MD-2. FEMS Immunol. Med. Microbiol. 51:84–91.CrossRefPubMedGoogle Scholar
  23. 23.
    Hornef MW, Normark BH, Vandewalle A, Normark S. (2003) Intracellular recognition of lipopolysaccharide by toll-like receptor 4 in intestinal epithelial cells. J. Exp. Med. 198:1225–35.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Sodhi CP, et al. (2012) Intestinal epithelial toll-like receptor 4 regulates goblet cell development and is required for necrotizing enterocolitis in mice. Gastroenterology. 143:708–18.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Holzenberger M, et al. (2000) Cre-mediated germline mosaicism: a method allowing rapid generation of several alleles of a target gene. Nucl. Acids Res. 28:E92.CrossRefPubMedGoogle Scholar
  26. 26.
    Scott MJ, Billiar TR. (2008) Beta2-integrin-induced p38 MAPK activation is a key mediator in the CD14/TLR4/MD2-dependent uptake of lipopolysaccharide by hepatocytes. J. Biol. Chem. 283:29433–46.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Buchholz BM, Billiar TR, Bauer AJ. (2010) Dominant role of the MyD88-dependent signaling pathway in mediating early endotoxin-induced murine ileus. Am. J. Physiol. Gastrointest. Liver Physiol. 299:G531–8.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Li J, et al. (2004) Recombinant HMGB1 with cytokine-stimulating activity. J. Immunol. Methods. 289:211–23.CrossRefPubMedGoogle Scholar
  29. 29.
    Brunn GJ, Bungum MK, Johnson GB, Platt JL. (2005) Conditional signaling by Toll-like receptor 4. FASEB J. 19:872–4.CrossRefPubMedGoogle Scholar
  30. 30.
    Kaczorowski DJ, et al. (2010) Pivotal advance: the pattern recognition receptor ligands lipopolysaccharide and polyinosine-polycytidylic acid stimulate factor B synthesis by the macrophage through distinct but overlapping mechanisms. J. Leukoc. Biol. 88:609–18.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Vakkila J, DeMarco RA, Lotze MT. (2004) Imaging analysis of STAT1 and NF-kappaB translocation in dendritic cells at the single cell level. J. Immunol. Methods. 294:123–34.CrossRefPubMedGoogle Scholar
  32. 32.
    Vakkila J, Demarco RA, Lotze MT. (2008) Coordinate NF-kappaB and STAT1 activation promotes development of myeloid type 1 dendritic cells. Scand. J. Immunol. 67:260–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Yu M, et al. (2006) HMGB1 signals through tolllike receptor (TLR) 4 and TLR2. Shock. 26:174–9.CrossRefGoogle Scholar
  34. 34.
    Kim JI, et al. (2005) Crystal structure of CD14 and its implications for lipopolysaccharide signaling. J. Biol. Chem. 280:11347–51.CrossRefPubMedGoogle Scholar
  35. 35.
    Tang D, et al. (2010) Endogenous HMGB1 regulates autophagy. J. Cell Biol. 190:881–92.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Tang D, Kang R, Zeh HJ 3rd, Lotze MT. (2011) High-mobility group box 1, oxidative stress, and disease. Antioxid. Redox Signal. 14:1315–35.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Schiraldi M, et al. (2012) HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J. Exp. Med. 209:551–63.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Tsung A, et al. (2007) HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J. Exp. Med. 204:2913–23.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Fan J, et al. (2007) Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role of HMGB1-TLR4 signaling. J. Immunol. 178:6573–80.CrossRefPubMedGoogle Scholar
  40. 40.
    Levy RM, et al. (2007) Systemic inflammation and remote organ injury following trauma require HMGB1. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293:R1538–44.CrossRefGoogle Scholar
  41. 41.
    Kaczorowski DJ, et al. (2009) Mechanisms of Tolllike receptor 4 (TLR4)-mediated inflammation after cold ischemia/reperfusion in the heart. Transplantation. 87:1455–63.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Wu H, et al. (2010) HMGB1 contributes to kidney ischemia reperfusion injury. J. Am. Soc. Nephrol. 21:1878–90.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Wu H, et al. (2007) TLR4 activation mediates kidney ischemia/reperfusion injury. J. Clin. Invest. 117:2847–59.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Shichita T, Sakaguchi R, Suzuki M, Yoshimura A. (2012) Post-ischemic inflammation in the brain. Front. Immunol. 3:132.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Su X, Wang H, Zhao J, Pan H, Mao L. (2011) Beneficial effects of ethyl pyruvate through inhibiting high-mobility group box 1 expression and TLR4/NF-kappaB pathway after traumatic brain injury in the rat. Mediators Inflamm. 2011:807142.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Kruger B, et al. (2010) Islet-expressed TLR2 and TLR4 sense injury and mediate early graft failure after transplantation. Eur. J. Immunol. 40:2914–24.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Maroso M, et al. (2010) Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat. Med. 16:413–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Mittal D, et al. (2010) TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J. 29:2242–52.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Nadatani Y, et al. (2012) High mobility group box 1 promotes small intestinal damage induced by nonsteroidal anti-inflammatory drugs through toll-like receptor 4. Am. J. Path. 181:98–110.CrossRefPubMedGoogle Scholar
  50. 50.
    Miller SI, Ernst RK, Bader MW. (2005) LPS, TLR4 and infectious disease diversity. Nat. Rev. Microbiol. 3:36–46.CrossRefPubMedGoogle Scholar
  51. 51.
    Triantafilou M, Triantafilou K. (2003) Receptor cluster formation during activation by bacterial products. J. Endotoxin Res. 9:331–5.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2013

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Sodam Kim
    • 1
  • Sun Young Kim
    • 1
  • John P. Pribis
    • 1
  • Michael Lotze
    • 1
  • Kevin P. Mollen
    • 1
  • Richard Shapiro
    • 1
  • Patricia Loughran
    • 1
  • Melanie J. Scott
    • 1
  • Timothy R. Billiar
    • 1
  1. 1.Department of Surgery, F1281, Presbyterian University HospitalUniversity of Pittsburgh Medical CenterPittsburghUSA

Personalised recommendations